Business Context and Reporting Period
This Form 8-K Current Report is filed by Seres Therapeutics, Inc. (Nasdaq: MCRB) for the reporting period of May 30, 2026. The filing addresses a corporate governance event involving the departure of a board member.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or operational metrics.
Material Changes
The material change reported is the resignation of Hans-Juergen Woerle, M.D., Ph.D., from his position as a member of the board of directors and all associated committees. The resignation is effective May 31, 2026.
Management Commentary and Risks
Management explicitly states that Dr. Woerle's departure is not due to any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. No other risks, contingencies, or unusual items are disclosed in this filing.
Investor Verification Checklist
- Verify the effective date of the board vacancy (May 31, 2026).
- Confirm whether the Company has announced a search for a replacement director.
- Review subsequent filings for any impact on committee compositions or quorum requirements.